BioFocus DPI Expands Ion Channel Offering Through Agreement With ChanTest Corporation

Published: Feb 06, 2013

Saffron Walden, UK (6 February 2013) – BioFocus and ChanTest today announced an agreement which will enable BioFocus to offer ChanTest’s extensive cell line library (> 200 products) and Channel PanelTM profiling services. This expands BioFocus’ offering in the fields of ion channel, GPCR and transporter targets for drug discovery.

“With access to ChanTest’s cell line collection and ion channel profiling, we have further augmented our suite of integrated drug discovery services, designed to deliver efficiency and success to our partners,” said Kate Hilyard, VP Biological Sciences, BioFocus.

Chris Mathes, Ph.D., M.B.A, Chief Commercial Officer, ChanTest, commented, “This collaboration with BioFocus fits well with ChanTest’s integrated CRO strategy, and we are delighted to partner with a company with such a strong reputation.”


Media enquiries

Katie Odgaard

Zyme Communications

Tel: +44 7787 502 947


At BioFocus:

Chris Newton

Tel: +44 1799 533 500


About BioFocus

BioFocus provides integrated drug discovery that delivers pre-clinical drug candidates in all therapeutic areas with strong capabilities in neurodegenerative diseases, inflammatory diseases and rare and neglected diseases. BioFocus has advanced and comprehensive drug discovery capabilities that are applied to client projects to deliver targets, hits, leads and pre-clinical candidates. The company employs over 150 exceptionally qualified and industry experienced scientists at its research centers in the UK and the Netherlands. Since its foundation in 1997, BioFocus has produced high quality data for its clients, assured by ISO9001 qualification, validated by regular independent inspection of all BioFocus research centers. More information can be found at

About ChanTest

ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the CRO has tested compounds for more than 500 global pharmaceutical and biotechnology companies and partners with them to speed the drug development process for the release of better, safer drugs. ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines and nonclinical cardiac risk assessment service portfolio is the most comprehensive commercially available today. ChanTest recently became the first ion channel CRO to offer cGMP bioassays and cell banking services. ChanTest is based in Cleveland, Ohio and works with clients in Europe through UK-based distributor Cambridge Bioscience ( For more information, e-mail

Back to news